IBDEI0GI ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7981,1,2,0)
 ;;=2^Intravitreal Inj of Eye Drug
 ;;^UTILITY(U,$J,358.3,7981,1,3,0)
 ;;=3^67028
 ;;^UTILITY(U,$J,358.3,7982,0)
 ;;=J9035^^51^575^3^^^^1
 ;;^UTILITY(U,$J,358.3,7982,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7982,1,2,0)
 ;;=2^Bevacizumab Inj 10mg
 ;;^UTILITY(U,$J,358.3,7982,1,3,0)
 ;;=3^J9035
 ;;^UTILITY(U,$J,358.3,7983,0)
 ;;=J2778^^51^575^5^^^^1
 ;;^UTILITY(U,$J,358.3,7983,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7983,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,7983,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,7984,0)
 ;;=J3301^^51^575^4^^^^1
 ;;^UTILITY(U,$J,358.3,7984,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7984,1,2,0)
 ;;=2^Kenalog Inj per 10mg
 ;;^UTILITY(U,$J,358.3,7984,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,7985,0)
 ;;=J0178^^51^575^2^^^^1
 ;;^UTILITY(U,$J,358.3,7985,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7985,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,7985,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,7986,0)
 ;;=4450F^^51^576^2^^^^1
 ;;^UTILITY(U,$J,358.3,7986,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7986,1,2,0)
 ;;=2^Self-Care Ed Provided to Pt
 ;;^UTILITY(U,$J,358.3,7986,1,3,0)
 ;;=3^4450F
 ;;^UTILITY(U,$J,358.3,7987,0)
 ;;=4177F^^51^576^3^^^^1
 ;;^UTILITY(U,$J,358.3,7987,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7987,1,2,0)
 ;;=2^Talk Pt/Crgvr Re AREDS
 ;;^UTILITY(U,$J,358.3,7987,1,3,0)
 ;;=3^4177F
 ;;^UTILITY(U,$J,358.3,7988,0)
 ;;=4174F^^51^576^1^^^^1
 ;;^UTILITY(U,$J,358.3,7988,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7988,1,2,0)
 ;;=2^Couns Potent Glauc Impct
 ;;^UTILITY(U,$J,358.3,7988,1,3,0)
 ;;=3^4174F
 ;;^UTILITY(U,$J,358.3,7989,0)
 ;;=373.32^^52^577^48
 ;;^UTILITY(U,$J,358.3,7989,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7989,1,3,0)
 ;;=3^Eyelid,Dermatitis,Allergic
 ;;^UTILITY(U,$J,358.3,7989,1,4,0)
 ;;=4^373.32
 ;;^UTILITY(U,$J,358.3,7989,2)
 ;;=^269061
 ;;^UTILITY(U,$J,358.3,7990,0)
 ;;=373.00^^52^577^4
 ;;^UTILITY(U,$J,358.3,7990,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7990,1,3,0)
 ;;=3^Blepharitis
 ;;^UTILITY(U,$J,358.3,7990,1,4,0)
 ;;=4^373.00
 ;;^UTILITY(U,$J,358.3,7990,2)
 ;;=Blepharitis^15271
 ;;^UTILITY(U,$J,358.3,7991,0)
 ;;=373.2^^52^577^7
 ;;^UTILITY(U,$J,358.3,7991,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7991,1,3,0)
 ;;=3^Chalazion
 ;;^UTILITY(U,$J,358.3,7991,1,4,0)
 ;;=4^373.2
 ;;^UTILITY(U,$J,358.3,7991,2)
 ;;=^22156
 ;;^UTILITY(U,$J,358.3,7992,0)
 ;;=374.84^^52^577^29
 ;;^UTILITY(U,$J,358.3,7992,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7992,1,3,0)
 ;;=3^Eyelid Cysts
 ;;^UTILITY(U,$J,358.3,7992,1,4,0)
 ;;=4^374.84
 ;;^UTILITY(U,$J,358.3,7992,2)
 ;;=^269119
 ;;^UTILITY(U,$J,358.3,7993,0)
 ;;=374.87^^52^577^31
 ;;^UTILITY(U,$J,358.3,7993,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7993,1,3,0)
 ;;=3^Eyelid Dermatochalasis
 ;;^UTILITY(U,$J,358.3,7993,1,4,0)
 ;;=4^374.87
 ;;^UTILITY(U,$J,358.3,7993,2)
 ;;=^269123
 ;;^UTILITY(U,$J,358.3,7994,0)
 ;;=375.15^^52^577^12
 ;;^UTILITY(U,$J,358.3,7994,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7994,1,3,0)
 ;;=3^Dry Eye Syndrome
 ;;^UTILITY(U,$J,358.3,7994,1,4,0)
 ;;=4^375.15
 ;;^UTILITY(U,$J,358.3,7994,2)
 ;;=Dry Eye Syndrome^37168
 ;;^UTILITY(U,$J,358.3,7995,0)
 ;;=374.01^^52^577^20
 ;;^UTILITY(U,$J,358.3,7995,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7995,1,3,0)
 ;;=3^Entropion, Senile
 ;;^UTILITY(U,$J,358.3,7995,1,4,0)
 ;;=4^374.01
 ;;^UTILITY(U,$J,358.3,7995,2)
 ;;=Entropion, Senile^269074
 ;;^UTILITY(U,$J,358.3,7996,0)
 ;;=375.20^^52^577^68
 ;;^UTILITY(U,$J,358.3,7996,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7996,1,3,0)
 ;;=3^Lacrimal,Epiphora
